The Skill to Heal. The Heart to Care.

Phone: 505.842.8171

dotAfter Hours: 505.857.3877

dotPharmacy: 505.822.3911




Latest Cancer News

DNAtrix Announces Treatment Of First Patient With DNX-2401 In Recurrent Glioblastoma Trial (09-19-2014)

DNAtrix, Inc., experts in oncolytic virus development, today announced that the first patient was treated with the company’s lead product, DNX-2401, a replication competent adenovirus plus gamma interferon in a randomized, multicenter, open-label... Continue Reading

Bayer and Orion Initiate Phase III Trial of Novel Prostate Cancer Agent ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer (09-18-2014)

Bayer HealthCare and Orion Corporation, a pharmaceutical company based in Espoo, Finland, have begun to enroll patients in a Phase III trial with ODM-201, an investigational novel oral androgen receptor (AR) inhibitor in clinical development for the treatment... Continue Reading

Breast Conservation Therapy May Be Better than a Mastectomy (09-17-2014)

Breast cancer claims the lives of approximately 40,000 women annually in the United States alone. Early-stage breast cancer refers to cancer that has not spread from its site of origin. Patients with early-stage breast cancer have a high cure rate with... Continue Reading

Vaccine Derived from HER2 Protein May Help Prevent Breast Cancer Recurrence (09-16-2014)

A new breast cancer vaccine that is derived from the HER2 protein may help prevent recurrence in patients with HER2-positive disease and appears safe. Phase II study results of the vaccine were released at the 2014 Breast Cancer Symposium, September 4–6,... Continue Reading

FDA Approves Use of Xtandi for Chemotherapy Naïve Men With Advanced Prostate Cancer (09-15-2014)

The FDA approved the use of Xtandi® (enzalutamide) in men who have not yet received chemotherapy, significantly expanding the potential patient population eligible to be treated with the oral medicine.  Xtandi originally gained U.S. approval in 2012... Continue Reading

New Survey Reveals that Prostate Cancer Impacts Sex Lives More than Any Other Aspect of Patients’ Lives (09-11-2014)

Washington, DC (September 8, 2014) – A recent survey conducted by ZERO – The End of Prostate Cancer and Ferring Pharmaceuticals Inc. aimed to uncover the impact of prostate cancer on patients, their caregivers, and the healthcare professionals (HCPs)... Continue Reading

Promising Activity of Imbruvica Plus Rituxan in High-Risk CLL (09-10-2014)

Researchers from MD Anderson Cancer Center recently reported in the journal The Lancet Oncology that the combination of Imbruvica® (ibrutinib) and Rituxan® (rituximab) showed promising activity in the management of patients with high-risk chronic... Continue Reading

New Guidelines on Treatment of HER2-Negative Breast Cancer Aim to Improve Patient Outcomes (09-9-2014)

The American Society of Clinical Oncology (ASCO) recently released updated guidelines for the treatment of advanced HER2-negative breast cancer. The Journal of Clinical Oncology will publish the new guidelines, which include hormone therapy and sequential... Continue Reading

Molecular Subtyping Can Improve Breast Cancer Treatment (09-8-2014)

IRVINE, CA and AMSTERDAM – In findings that may eventually change the way breast cancer is evaluated and treated, a new study reports that the BluePrint genomic test provides more accurate information about the molecular subtype of a specific breast... Continue Reading

Pembrolizumab Gets FDA Approval in Advanced Melanoma (09-5-2014)

The U.S. Food & Drug Administration (FDA) has granted approval to Merck’s new immunotherapy drug, Keytruda (pembrolizumab), for treating metastatic melanoma.   It is the first anti-PD-1 drug, aimed at re-energizing a patient’s protective immune... Continue Reading

Adding Revlimid to R-CHOP May Improve Outomes of Selected Patients with NHL (09-4-2014)

The results of a recently completed study reported in the Journal of Clinical Oncology indicate that the addition of Revlimid® (lenalidomide) to R-CHOP the standard treatment for non hodgkin lymphoma (NHL) can overcome the negative prognostic effect... Continue Reading

Cabozantinib Development in Prostate Cancer Halted (09-3-2014)

Development of the investigational drug cabozantinib that initially showed promise in the treatment of metastatic, hormone-refractory prostate cancer has been halted due to discouraging results in a pivotal clinical trial.  Enrollment in a second, phase... Continue Reading

Next Page »